home / stock / obsv / obsv news

OBSV News and Press, ObsEva SA From 05/13/19

Stock Information
Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com
Menu
OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...
OBSV - ObsEva SA (OBSV) CEO Ernest Loumaye on Q1 2019 Results - Earnings Call Transcript

ObsEva SA (OBSV) Q1 2019 Results Earnings Conference Call May 09, 2019 08:00 AM ET Company Participants Mario Corso - Senior Director, Investor Relations Ernest Loumaye - Co-Founder and Chief Executive Officer Jean-Pierre Gotteland - Chief Scientific Officer Wim Souverijns - Ch...
OBSV - ObsEva misses by $0.09

ObsEva (NASDAQ: OBSV ): Q1 GAAP EPS of -$0.59 misses by $0.09 . More news on: ObsEva SA, Earnings news and commentary, Healthcare stocks news, Read more ...

OBSV - ObsEva Reports First Quarter 2019 Financial Results

  2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids;                 MAA submission for nolasiban IVF therapy targeted by year-end   GENEVA, Switzerland and BOSTON, MA. (May 9, 2019...

OBSV - ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive hea...
OBSV - ObsEva SA Announces that ObsEva's Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019

Geneva, Switzerland and Boston, MA – May 8, 2019  - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive hea...

OBSV - ObsEva's linzagolix shows long-term effect in extension study

Long-term data from a Phase 2b clinical trial, EDELWEISS , evaluating ObsEva SA's (NASDAQ: OBSV ) linzagolix for the treatment of endometriosis-associated pelvic pain showed a durable treatment benefit with the daily 75 mg and 200 mg doses. More news on: ObsEva SA, Healthcare stocks ne...

OBSV - ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain

                     Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel thera...
OBSV - ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019

Geneva, Switzerland and Boston, MA –May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive healt...

OBSV - ObsEva SA reports follow-up data from IMPLANT2 trial

ObsEva SA (NASDAQ: OBSV ) announces additional neonatal and infant follow-up results from the IMPLANT2 Phase 3 trial of its oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF procedures. More news on: ObsEva SA, Healthcare stocks news, Read more ...

OBSV - ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive h...
Previous 10 Next 10